Universidad de Alcalá-OTRI

Compounds for the treatment of Leishmania infections

Posted by Universidad de Alcalá-OTRIResponsive · Patents for licensing · Spain

Summary of the technology

The research group Heterobetainas of the University of Alcalá presents the preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML).

The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical

Universidad de Alcalá-OTRI
Universidad de Alcalá-OTRI

Description of the technology

Parasites of the genus Leishmania are the cause of leishmaniasis, a disease present in 22 countries of America and 66 nations of the old world, with special incidence in Southeast Asia, East Africa and Brazil. In Europe it is possible to find cases of infection in humans in 16 countries, including France, Italy, Greece, Malta, Spain and Portugal.

The treatment of Leishmaniasis is based today on the use of anti-Leishmania drugs and on an aggressive control of any concomitant bacterial or parasitic infection, a possible anemia, hypovolemia and malnutrition.

Despite the existence of some treatments there is still a great need to advance in the research and development of new drugs that are less toxic and with fewer side effects.

In this sense, the preparation and use of the structures of pyridazino [1 ', 6': 1,2] pyrido [3,4-b] indolinium salts presented by this research group at the University of Alcalá can be an interesting solution for the treatment of the disease, the infections caused by the parasite and to inhibit the growth of this one. The present invention relates to a pharmaceutical composition comprising at least one of the compounds of the invention, together with a pharmaceutically acceptable vehicle.

The pharmaceutically acceptable adjuvants and vehicles that can be used in said compositions are the adjuvants and vehicles known to those skilled in the art and commonly used in the preparation of therapeutic compositions.

INNOVATIVE ASPECTS

The compounds of the invention produce less toxicity and fewer side effects in the patient.

The compounds of the invention are pharmaceutically acceptable salts, prodrugs and / or solvates, as well as pharmaceutical compositions containing them. They can be used together with other drugs, or additional active ingredients, to provide a combination therapy.

Nothing similar has been found in the scientific literature consulted

COMPETITIVE ADVANTAGES

This new result has good specificity for the Leishmania parasite and would be a competitive advantage for that pharmaceutical company that would manufacture an active ingredient for the formulation of a leishmanicidal drug.

Given the similarity of the different species of Leishmania, the compounds of the invention are used for the treatment of any type of leishmaniasis. Both visceral (LV) and mucocutaneous (LMC).

The therapeutic composition can be prepared in solid form or aqueous suspension, in a pharmaceutically acceptable diluent.

It can be administered by any appropriate route of administration: oral, topical, rectal or parenteral.

 

Current development status

Experimental technologies

Applications

formulation of a leishmanicidal drug based on these compounds

Desired business relationship

Technology selling

Patent licensing

Technology development

The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical

Intellectual property status

Granted Patent
The patent has been granted by the OEPM with reference ES2526935
http://www.oepm.es/pdf/ES/0000/000/02/52/69/ES-2526935_A1.pdf

Technology Owner

Universidad de Alcalá-OTRI

Research & Technology Organization

Related keywords

  • Biological Sciences
  • Medicine, Human Health
  • Clinical Research, Trials
  • Medical Research
  • Pharmaceutical Products / Drugs
  • Virus, Virology / Antibiotics / Bacteriology
  • Biology / Biotechnology
  • In vitro Testing, Trials Technology
  • Microbiology Technology
  • Toxicology Technology
  • Medical Health related
  • Therapeutic
  • Anatomy, Pathology, Immunology, Physiology
  • drugs
  • antiparasitic
  • parasites
  • pathogens
  • antiprotozoal
  • leishmanicidal
  • leishmaniasis
  • leishmania
  • new drugs
  • compounds
  • drug discovery

About Universidad de Alcalá-OTRI

Research & Technology Organization from Spain

The Technology Transfer Office at Alcalá University serves as a liaison between the University and its socioeconomic environment in terms of research and innovation. It encorages collaboration between research groups from universities and companies/institutions, with the objective to promote and commercialize research results and scientific capabilities.

Some of the services offered by this office are specified in the following list:

- Promotion of R & D and improvement of the relationships with companies.
- Promote the participation in R & D projects applicants to public calls (regional, national and European).
- Advising, processing and monitoring of patents and other forms of industrial protection.
- Support in the negotiation of contracts and agreements for R&D&i

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.